Clearside Biomedical

Clearside Biomedical Earnings Yield

Delisted

The Earnings Yield of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -975.91 %. In the previous year, Earnings Yield was -922.87 % — a change of 5.75% (lower).

Earnings Yield

-975.91 %

YoY

5.75%

Last updated:

Earnings Yield of Clearside Biomedical is 2024 -975.91 % . Earnings Yield of Clearside Biomedical was 2023 -922.87 % . It decreases by 5.75% lower compared to the previous year.

The Clearside Biomedical Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2017
-1,675.57 USD
Jan 1, 2018
-2,352.84 USD
Jan 1, 2019
-874.15 USD
Jan 1, 2020
-517.33 USD
Jan 1, 2021
10.80 USD
Jan 1, 2022
-936.08 USD
Jan 1, 2023
-922.87 USD
Jan 1, 2024
-975.91 USD
The Clearside Biomedical Earnings Yield history
YEAREarnings YieldYoY
-975.91 %+5.75%
-922.87 %-1.41%
-936.08 %-8,771.05%
10.80 %-102.09%
-517.33 %-40.82%
-874.15 %-62.85%
-2,352.84 %+40.42%
-1,675.57 %+127.90%
-735.23 %+46.71%
-501.14 %+73.11%
-289.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Earnings Yield of Clearside Biomedical is -975.91 % in 2024.

Earnings Yield of Clearside Biomedical changed from -922.87 % to -975.91 %, representing a 5.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Clearside Biomedical

All Key Metrics — Clearside Biomedical